肿瘤防治研究2017，Vol.44Issue(3)：225-230,6.DOI:10.3971/j.issn.1000-8578.2017.03.014
非小细胞肺癌EGFR-TKI耐药机制及治疗策略
Mechanism and Strategies on Drug Resistance of Non-small Cell Lung Cancer to EGFR-TKI
陈蕊 1赵达 1王丽娜2
作者信息
- 1. 730000兰州,兰州大学第一医院肿瘤内科
- 2. 730000兰州,兰州大学第一医院放疗科
- 折叠
摘要
Abstract
Non-small cell lung cancer(NSCLC) accounts for about 80％ of all lung cancer.There is a great many NSCLC patients have been in advanced stage when diagnosed.As a result,people pay more attention to curing advanced NSCLC.The standard treatment to advanced NSCLC is platinum-based combined chemotherapy.Then exploring new therapies is extremely urgent to us.With the development of medical molecular biology techniques and the study of molecular pathogenesis of lung cancer,epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(TKIs) such as gefitinib and erlotinib are becoming promising therapies for parts of patients with NSCLC.The compounds which target the EGFR play an important role in the treatment of the NSCLC.However,after a period of treatment(median time is 6 to 12 months),most patients will develop drug resistance to EGFR-TKIs.Intense research in these NSCLCs has identified two major mechanisms of resistance to TKIs:Primary and acquired resistances.The aim of this article was to summarize the development of the resistance mechanisms and new overcoming strategies on better treatment of drug resistant cancer cells in EGFR-mutant NSCLC.关键词
表皮生长因子受体/非小细胞肺癌/酪氨酸激酶抑制剂/耐药/突变Key words
EGFR/NSCLC/TKIs/Drug resistances/Mutant分类
医药卫生引用本文复制引用
陈蕊,赵达,王丽娜..非小细胞肺癌EGFR-TKI耐药机制及治疗策略[J].肿瘤防治研究,2017,44(3):225-230,6.
